Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMEETH VEDRE

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1578643474
CMS profile
117185
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,693.60

90 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,252.48 88
Travel and Lodging $441.12 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMEETH VEDRE

NPI 1578643474 · CMS profile ID 117185

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578643474?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMEETH VEDRE, NPI 1578643474, CMS profile ID 117185. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578643474?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AMEETH VEDRE, NPI 1578643474, CMS profile ID 117185. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578643474?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AMEETH VEDRE, NPI 1578643474, CMS profile ID 117185, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578643474?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

90 matching records · $2,693.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 90 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–90 of 90.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kiniksa Pharmaceuticals, Ltd. $15.2605/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058960175 CMS
Alnylam Pharmaceuticals Inc. $28.1305/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006152609 CMS
E.R. Squibb & Sons, L.L.C. $4.0705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015723718 CMS
Azurity Pharmaceuticals, Inc. $17.9305/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 989004561 CMS
E.R. Squibb & Sons, L.L.C. $4.5905/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015723721 CMS
Merck Sharp & Dohme LLC $17.6505/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048544839 CMS
Bayer Healthcare Pharmaceuticals Inc. $34.2804/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000421549 CMS
Bayer Healthcare Pharmaceuticals Inc. $34.2804/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000421557 CMS
Bayer Healthcare Pharmaceuticals Inc. $75.4204/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000422788 CMS
Bayer Healthcare Pharmaceuticals Inc. $78.6704/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000422987 CMS
Bayer Healthcare Pharmaceuticals Inc. $89.1304/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000423345 CMS
Bayer Healthcare Pharmaceuticals Inc. $362.4504/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000426403 CMS
PFIZER INC. $28.2504/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050270285 CMS
Novartis Pharmaceuticals Corporation $6.4304/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993347603 CMS
Edwards Lifesciences Corporation $143.8504/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023203069 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $13.2504/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984087887 CMS
E.R. Squibb & Sons, L.L.C. $16.7004/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015723709 CMS
E.R. Squibb & Sons, L.L.C. $9.1603/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015723701 CMS
Merck Sharp & Dohme LLC $31.6803/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048544835 CMS
E.R. Squibb & Sons, L.L.C. $6.4903/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015723705 CMS
Kiniksa Pharmaceuticals, Ltd. $23.3303/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142997126 CMS
PFIZER INC. $85.4803/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050270889 CMS
Amgen Inc. $113.8503/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019794029 CMS
Novartis Pharmaceuticals Corporation $15.2403/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993347609 CMS
Janssen Pharmaceuticals, Inc $12.9803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987877581 CMS
Novartis Pharmaceuticals Corporation $17.2502/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993347607 CMS
E.R. Squibb & Sons, L.L.C. $20.9302/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015723679 CMS
Merck Sharp & Dohme LLC $17.4402/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048817891 CMS
E.R. Squibb & Sons, L.L.C. $91.9502/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015723689 CMS
PFIZER INC. $27.3702/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049293237 CMS
Medtronic, Inc. $127.5002/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026008245 CMS
Amgen Inc. $13.6702/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019794021 CMS
Merck Sharp & Dohme LLC $16.5301/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048544841 CMS
Amgen Inc. $17.1601/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019794017 CMS
Novartis Pharmaceuticals Corporation $11.0701/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993347605 CMS
Azurity Pharmaceuticals, Inc. $14.9601/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991803659 CMS
Amgen Inc. $24.1201/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019794013 CMS
Merck Sharp & Dohme LLC $96.6901/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048544837 CMS
Amgen Inc. $5.3401/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019794009 CMS
Lilly USA, LLC $18.5801/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031254613 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $465.70 23
PY2020 $1,052.71 60
PY2021 $1,531.75 76
PY2022 $1,539.24 71
PY2023 $2,693.60 90
PY2024 $1,598.59 74
PY2025 $1,385.42 58

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,544.92 38
PY2024 Principal investigator $230,774.18 7
PY2023 Principal investigator $75,580.32 6
PY2022 Principal investigator $43,945.77 4
PY2021 Principal investigator $37,421.15 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 12/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1190306341
Principal investigator 1 Ionis Pharmaceuticals, Inc. $460.00 11/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246790638
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,360.10 11/19/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190306337
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,750.00 10/31/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789943
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/28/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643959
Principal investigator 1 Boehringer Ingelheim International GmbH $14,000.00 10/28/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643961
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/28/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643963
Principal investigator 1 Boehringer Ingelheim International GmbH $2,618.00 10/28/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643965
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/28/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643967
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/28/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643971
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/28/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643973
Principal investigator 1 Ionis Pharmaceuticals, Inc. $575.00 10/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789220
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,700.00 10/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789224
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,725.00 10/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789229
Principal investigator 1 Ionis Pharmaceuticals, Inc. $8,250.00 10/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789234
Principal investigator 1 Ionis Pharmaceuticals, Inc. $15,000.00 10/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789239
Principal investigator 1 Ionis Pharmaceuticals, Inc. $58,211.08 10/14/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789243
Principal investigator 1 Boehringer Ingelheim International GmbH $1,016.00 10/02/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643953
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643955
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/02/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643957
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643969
Principal investigator 1 Verona Pharma, Inc. $3,779.60 09/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) No dispute reported 06/30/2026 1232891711
Principal investigator 1 Verona Pharma, Inc. $252.00 09/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) No dispute reported 06/30/2026 1232891713
Principal investigator 1 Verona Pharma, Inc. $252.00 09/26/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) No dispute reported 06/30/2026 1232891717
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,550.00 09/24/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEA
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185543112
Principal investigator 1 Verona Pharma, Inc. $5,547.60 08/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) No dispute reported 06/30/2026 1232891709
Principal investigator 1 Ionis Pharmaceuticals, Inc. $920.00 08/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246785994
Principal investigator 1 Ionis Pharmaceuticals, Inc. $920.00 08/05/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246786003
Principal investigator 1 Verona Pharma, Inc. $2,747.80 08/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) No dispute reported 06/30/2026 1232891707
Principal investigator 1 Verona Pharma, Inc. $750.00 08/01/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINIC
A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore) No dispute reported 06/30/2026 1232891715
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 07/27/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643951
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643945
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 05/27/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643947
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220643949
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 05/13/2025 Non-covered Recipient Entity
First Coast Heart And Vascular Center
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220995076
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,625.00 03/17/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1190300441
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,923.66 02/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190300431
Principal investigator 1 Novartis Pharmaceuticals Corporation $450.00 02/27/2025 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1190300445